Back to discover
Drug

Uracil

In clinical development
Emerging researchLate-stage developmentRising momentum
7
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Thyroid hormone and the Liver.

Research2024-12-20Hepatology communications

The first MASH drug therapy on the horizon: Current perspectives of resmetirom.

Research2024-04-05Liver international : official journal of the International Association for the Study of the Liver

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Uracil
RxNorm CUI
10995
ChEMBL ID
CHEMBL566
UNII
56HH86ZVCT

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2010
1
Late-stage (III+)
2
Completed
PHASE DISTRIBUTIONn = 2
Phase 11Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Research activity

7 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20232025
Most influential
Recent papers
Major research themes8
Fatty Liver3Liver2Non-alcoholic Fatty Liver Disease2Thyroid Hormone Receptors beta2Cardiomyopathy, Hypertrophic1Colonic Neoplasms1Colorectal Neoplasms1Magnetic Resonance Imaging, Cine1
Journals, researchers & institutions
Top journals
  • Diabetes, obesity & metabolism1
  • Hepatology communications1
  • Journal of hepatology1
  • Journal of the American College of Cardiology1
  • Liver international : official journal of the International Association for the Study of the Liver1
  • Metabolism: clinical and experimental1
Leading researchers
  • Targher G2
  • Abraham TP1
  • Aghemo A1
  • Amellal N1
  • Benhadji KA1
  • Bondarenko I1
  • Boutari C1
  • Bruinstroop E1
Leading institutions
free-text, unnormalised
  • Oregon Health and Science University2
  • University of Verona2
  • Beth Israel Deaconess Medical Center1
  • Biological Resource Center Unit1
  • Boston University Chobanian & Avedisian School of Medicine1
  • Brigham and Women's Hospital1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 5 of the same disease areas as Uracil in the shared literature.

5 shared diseases5 shared papers

Studied across 3 of the same disease areas as Uracil in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Uracil in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Uracil in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials